GDXJ vs. CRVS

Last updated Jun 13, 2026

GDXJ (VanEck Junior Gold Miners ETF) is Gold fund tracking the MVIS Global Junior Gold Miners Index, while CRVS (Corvus Pharmaceuticals, Inc.) is a stock. Over the past 10 years, GDXJ returned 12.00%/yr vs 0.06%/yr for CRVS. At a 0.12 correlation, their price movements are largely independent.

Performance

GDXJ vs. CRVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in VanEck Junior Gold Miners ETF (GDXJ) and Corvus Pharmaceuticals, Inc. (CRVS). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, GDXJ achieves a -8.37% return, which is significantly lower than CRVS's 54.94% return. Over the past 10 years, GDXJ has outperformed CRVS with an annualized return of 12.00%, while CRVS has yielded a comparatively lower 0.06% annualized return.

GDXJ

• 1D: 3.15%
• 1M: -19.14%
• YTD: -8.37%
• 6M: -6.68%
• 1Y: 51.06%
• 3Y*: 44.17%
• 5Y*: 16.23%
• 10Y*: 12.00%

CRVS

• 1D: 2.84%
• 1M: -24.68%
• YTD: 54.94%
• 6M: 42.53%
• 1Y: 181.37%
• 3Y*: 53.32%
• 5Y*: 33.63%
• 10Y*: 0.06%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GDXJ vs. CRVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GDXJ VanEck Junior Gold Miners ETF	-8.37%	172.28%	15.67%	7.12%	-14.53%	-21.25%	30.40%	40.44%	-11.02%	8.22%
CRVS Corvus Pharmaceuticals, Inc.	54.94%	43.93%	203.98%	107.06%	-64.73%	-32.30%	-34.56%	48.23%	-64.58%	-27.55%

Correlation

The correlation between GDXJ and CRVS is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.30
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (10Y) Calculated over the trailing 10-year period	0.12
Correlation (All Time) Calculated using the full available price history since Mar 23, 2016	0.12

The correlation between GDXJ and CRVS shifts across timeframes, from 0.12 (all time) to 0.30 (1 year), reflecting how their relationship changes across market environments.

Return for Risk

GDXJ vs. CRVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GDXJ

GDXJ Risk / Return Rank: 31
GDXJ Sharpe Ratio Rank: 31
GDXJ Sortino Ratio Rank: 30
GDXJ Omega Ratio Rank: 33
GDXJ Calmar Ratio Rank: 30
GDXJ Martin Ratio Rank: 28

CRVS

CRVS Risk / Return Rank: 86
CRVS Sharpe Ratio Rank: 73
CRVS Sortino Ratio Rank: 96
CRVS Omega Ratio Rank: 93
CRVS Calmar Ratio Rank: 85
CRVS Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GDXJ vs. CRVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for VanEck Junior Gold Miners ETF (GDXJ) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	GDXJ	CRVS	Difference
Sharpe ratio: Return per unit of total volatility	1.00	1.01	-0.01
Sortino ratio: Return per unit of downside risk	1.45	4.24	-2.79
Omega ratio: Gain probability vs. loss probability	1.20	1.48	-0.28
Calmar ratio: Return relative to maximum drawdown	1.30	3.23	-1.93
Martin ratio: Return relative to average drawdown	3.55	7.03	-3.48

GDXJ vs. CRVS - Sharpe Ratio Comparison

The current GDXJ Sharpe Ratio is 1.00, which is comparable to the CRVS Sharpe Ratio of 1.01. The chart below compares the historical Sharpe Ratios of GDXJ and CRVS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

GDXJ vs. CRVS - Drawdown Comparison

The maximum GDXJ drawdown since its inception was -88.66%, smaller than the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for GDXJ and CRVS.

Drawdown Indicators

	GDXJ	CRVS	Difference
Max Drawdown Largest peak-to-trough decline	-88.66%	-96.97%	+8.31%
Max Drawdown (1Y) Largest decline over 1 year	-39.47%	-56.43%	+16.96%
Max Drawdown (3Y) Largest decline over 3 years	-39.47%	-70.50%	+31.03%
Max Drawdown (5Y) Largest decline over 5 years	-49.76%	-92.40%	+42.64%
Max Drawdown (10Y) Largest decline over 10 years	-57.77%	-96.97%	+39.20%
Current Drawdown Current decline from peak	-33.25%	-53.25%	+20.00%
Average Drawdown Average peak-to-trough decline	-60.45%	-69.28%	+8.83%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.41%	25.91%	-11.50%

Volatility

GDXJ vs. CRVS - Volatility Comparison

The current volatility for VanEck Junior Gold Miners ETF (GDXJ) is 19.46%, while Corvus Pharmaceuticals, Inc. (CRVS) has a volatility of 23.12%. This indicates that GDXJ experiences smaller price fluctuations and is considered to be less risky than CRVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GDXJ	CRVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.46%	23.12%	-3.66%
Volatility (6M) Calculated over the trailing 6-month period	43.41%	111.88%	-68.47%
Volatility (1Y) Calculated over the trailing 1-year period	51.54%	180.64%	-129.10%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	41.50%	131.02%	-89.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	44.23%	111.13%	-66.90%

Dividends

GDXJ vs. CRVS - Dividend Comparison

GDXJ's dividend yield for the trailing twelve months is around 2.54%, while CRVS has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CRVS Corvus Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GDXJ VanEck Junior Gold Miners ETF	2.54%	2.33%	2.61%	0.72%	0.51%	1.78%	1.58%	0.39%	0.45%	0.03%	4.78%	0.72%

Frequently Asked Questions

Can I hold both GDXJ and CRVS in my portfolio?

GDXJ and CRVS have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, GDXJ or CRVS?

CRVS has higher volatility (23.12%) compared to GDXJ (19.46%). In terms of maximum drawdown, GDXJ dropped -88.66% vs CRVS's -96.97%.

Which has better risk-adjusted returns?

CRVS currently has the higher Sharpe Ratio (1.01 vs 1.00), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.